Sanofi(US:SNY) 3 6 Ke·2025-12-08 00:02Core Insights - The RSV (Respiratory Syncytial Virus) season this year has been unusually prolonged, with parents now having the option to vaccinate their children with a high-cost monoclonal antibody, Nirsevimab, developed by Sanofi, to reduce the risk of severe RSV infections [1][2] - Nirsevimab has gained significant traction in the market, generating substantial revenue in the U.S. and Europe, and is expected to continue its growth trajectory as it expands into other markets [7][8] Group 1: RSV Infection and Treatment Landscape - RSV is the leading cause of severe lower respiratory infections in infants, with hospitalization rates for infants under three months reaching 10%-20% [2] - Prior to Nirsevimab, the RSV prevention market was dominated by Palivizumab, which had a narrow application range and was not effective for the majority of infants [2][3] - Nirsevimab is advantageous as it can be administered to healthy infants, unlike Palivizumab, which is limited to high-risk groups [3][6] Group 2: Market Demand and Supply Challenges - The demand for Nirsevimab has surged, with approximately 2.4 million infants in the U.S. eligible for treatment during the 2024 RSV season, leading to significant supply shortages [6][8] - Sanofi reported that Nirsevimab generated approximately $598 million in sales in 2023, with projections of $1.829 billion in 2024, marking it as a blockbuster drug [7][8] Group 3: Competitive Landscape - The introduction of Clesrovimab, another monoclonal antibody for RSV prevention, is anticipated to further intensify competition in the market, with its approval expected in June 2025 [9][10] - Both Nirsevimab and Clesrovimab have similar indications, but Nirsevimab has a broader age range for application, which may give it a competitive edge [9][10] Group 4: Domestic Development and Future Prospects - In China, the development of RSV monoclonal antibodies is still in its early stages, with only a few candidates in clinical trials, such as TNM-001 and RB0026, which are expected to enter the market by 2027 [14][15][16] - The complexity and high failure rates associated with developing RSV monoclonal antibodies pose challenges for domestic companies, leading to a slower response in the market compared to vaccines [16][17]